The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
New horizons in adjuvants for vaccine development
Open accessAbstract
Adjuvant molecules, particularly toll like receptor (TLR) agonists have been in development for decades, though until now only a natural TLR 4 ligand (mono-phosphoryl lipid A, MPL) has been incorporated into licensed vaccine products, in formulations than enhance and complement the MPL activity. The inclusion of MPL-based formulations into vaccines has been based on enhancing antibody responses to subunit antigens, and has provided important proof-of-concept for enhancing desired immune responses to defined molecular targets. Challenges remain in adjuvant development, particularly for those that stimulated effective T cell responses for both preventative and therapeutic vaccines. The discovery of molecules, many based on RNA, that stimulate innate and adaptive immune responses and have the ability to stimulate potent CD8 T cell responses, has opened the door for development of a new generation of vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Toll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Immune Signaling by RIG-I-like Receptors
Loo, Y.-M., & Gale, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.003 · Cited by 1,875
Self-citationHow dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity
Gack, M. U., Shin, Y. C., Joo, C.-H., Urano, T., Liang, C., Sun, L., Takeuchi, O., Akira, S., Chen, Z., Inoue, S., et al. (2007) · Nature · doi:10.1038/nature05732 · Cited by 1,695
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Jiang, W., Swiggard, W. J., Heufler, C., Peng, M., Mirza, A., Steinman, R. M., & Nussenzweig, M. C. (1995) · Nature · doi:10.1038/375151a0 · Cited by 964
Cited by
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Self-citationBiomaterials for Nanoparticle Vaccine Delivery Systems
Sahdev, P., Ochyl, L. J., & Moon, J. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1419-y · Cited by 310
Plotkin, S. A. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00290-09 · Cited by 256
Kwissa, M., Nakaya, H. I., Oluoch, H., & Pulendran, B. (2012) · Blood · doi:10.1182/blood-2011-10-388579 · Cited by 132
Novel Vaccines to Human Rabies
Ertl, H. C. J. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000515 · Cited by 93
Metadata
- Authors
- Reed, S. G., Tomai, M., & Gale, M. J.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 65
- Pages
- 97-101
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W3091948925
- Cited by
- 554
- References
- 113
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New horizons in adjuvants for vaccine development. https://app.cochat.ai/papers/10.1016/j.coi.2020.08.008
- The paper
- Reed, S. G., Tomai, M., & Gale, M. J. (2020). New horizons in adjuvants for vaccine development. Current Opinion in Immunology. https://doi.org/10.1016/j.coi.2020.08.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
